2-DG dosing in published research varies considerably depending on the application — cancer, longevity, antiviral, or neuroprotection — and the study design.

In human phase I cancer trials, the maximum tolerated dose was established at approximately 200mg/kg as a single oral dose. The dose-limiting toxicity was hypoglycaemia-like symptoms: sweating, anxiety, and discomfort — consistent with glucose deprivation rather than true insulin-mediated hypoglycaemia.

For combination cancer protocols with radiation, doses of 150–250mg/kg given before each radiation fraction have been used in phase I/II trials. These are single-administration doses around treatment sessions, not daily dosing.

For longevity and AMPK activation research, animal model studies have used much lower intermittent doses — approximately 0.1% in food or water, equating to roughly 50–100mg/kg intermittently. The emphasis on intermittent dosing comes from cardiac toxicity observations with continuous high-dose administration.

Key safety consideration: 2-DG should not be taken in a fasted state, as the combination of low blood glucose from fasting plus hexokinase inhibition from 2-DG significantly increases hypoglycaemia risk. Dosing with food substantially reduces this risk.

This article is for informational and educational purposes only. AuraDCA products are intended for research use only.